Drugs / Nanocurcumin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT03140657 | Apr → Nov 2017 | ankylosing spondylitis | Tabriz University of Medical Sciences | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04989166 | Oct 2021 → Oct 2022 | acute pancreatitis | National Nutrition and Food Technology Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nano-curcumin | “This study aims to investigate the effect of nano-curcumin supplementation on hospital length of stay, clinical outcomes, and inflammation level in mild and moderate acute pancreatitis.” NCT04989166 ↗ |
| Known as | Exirnanosina | “Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina).” NCT03140657 ↗ |
| Route | Oral | “12 out of 24 received a daily dose of 80 mg oral nano-curcumin” NCT03140657 ↗ |